Kyverna Therapeutics | 10-Q:季度报表
Kyverna Therapeutics | 8-K:Kyverna Therapeutics提供最新业务并公布2024年第一季度财务业绩
Kyverna Therapeutics | SC 13D:超过5%持股股东披露文件-Vida Ventures, LLC(11.1%),VV Manager LLC(11.1%)等
Kyverna Therapeutics | 10-K:年度报表
Kyverna Therapeutics | 8-K:重大事件
Kyverna Therapeutics | SC 13G:超过5%持股股东披露文件-Michael P. Rubin(7.6%),Northpond Ventures III, LP(6.5%)等
Kyverna Therapeutics | SC 13G:超过5%持股股东披露文件-Gilead Sciences, Inc.(9 . 6%)
Kyverna Therapeutics | 4:持股变动声明-股东 Vida Ventures, LLC
Kyverna Therapeutics | 4:持股变动声明-董事 Cohen Fred E
Kyverna Therapeutics | 4:持股变动声明-董事 SEIDENBERG BETH C
Kyverna Therapeutics | 4:持股变动声明-股东 Westlake BioPartners Fund I, L.P.
Kyverna Therapeutics | 4:持股变动声明-股东 Bain Capital Life Sciences Investors, LLC
Kyverna Therapeutics | SC 13G:超过5%持股股东披露文件-Bain Capital Life Sciences Opportunities III, LP(7.4%)
Kyverna Therapeutics | 4:持股变动声明-股东 GILEAD SCIENCES, INC.
Kyverna Therapeutics | SEC STAFF LETTER:其他
Kyverna Therapeutics | 4:持股变动声明- Northpond Ventures III GP, LLC
Kyverna Therapeutics | 8-K:重大事件
Kyverna Therapeutics | S-8:员工福利计划证券登记
Kyverna Therapeutics | 424B4:募资说明书
Kyverna Therapeutics | CERT:其他
暂无数据